34376-54-0

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 106, p. 630, 1984 DOI: 10.1021/ja00315a030

InChI:InChI=1/C5H10N2O/c8-5-1-2-6-3-4-7-5/h6H,1-4H2,(H,7,8)/p+1

Upstream product

• 40064-34-4 4-piperidone monohydrochloride monohydrate 
• 55186-89-5 1-benzyl-1,4-diazepan-5-one 
• 29094-08-4 N-(2-Aminoethyl)-β-alanine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 40064-34-4 piperidine-4,4-diol hydrochloride 
• 949-69-9 N-benzyl-4-(N-hydroxyimino)piperidine 
• 41661-47-6 piperidin-4-one 
• 190900-21-1 5-oxo-[1,4]diazepane-1-carboxylic acid tert-butyl ester 

Downstream Products

• 122484-74-6 1-(2-ethoxyethyl)-2-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)-5-phenylmethoxy-1H-benzimidazole 
• 122484-84-8 1-(2-ethoxyethyl)-2-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)-6-phenylmethoxy-1H-benzimidazole 
• 190900-21-1 5-oxo-[1,4]diazepane-1-carboxylic acid tert-butyl ester 
• 122484-75-7 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-5-oxo-1H-1,4-diazepin-1-yl)-5-phenylmethoxy-1H-benzimidazole 
• 122484-85-9 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-5-oxo-1H-1,4-diazepin-1-yl)-6-phenylmethoxy-1H-benzimidazole 
• 800402-08-8 [1-(S)-(4-fluorobenzyl)-2-oxo-2-(5-oxo-[1,4]diazepam-1-yl)ethyl]carbamic acid ter-butyl ester 
• 888730-06-1 1-(2-fluoro-4-nitrophenyl)-1,4-diazepan-5-one 
• 890926-77-9 benzyl 5-tert-butyl-2-(5-oxo-1,4-diazepane-1-carbonyl)-1H-pyrrol-3-ylcarbamate 
• 18158-16-2 benzyl 5-oxo-1,4-diazepane-1-carboxylate 
• 1076243-00-9 C₁₂H₁₅ClN₂O 
• 147378-75-4 1-(3-Trifluoromethylphenyl)hexahydro-1,4-diazepin-5-one 
• 1421767-66-9 C₂₃H₂₃ClFN₅O₃ 
• 1076243-03-2 1-(4-chlorobenzyl)-4-[(2S)-oxiran-2-ylmethyl]-1,4-diazepan-5-one 

Relevant academic research and scientific papers

Ferrocene-Cyclam: A redox-active macrocycle for the complexation of transition metal ions and a study on the influence of the relative permittivity on the coulombic interaction between metal cations

The reaction of 1,1′-ferrocene-bis(methylenepyridinium) salt with 1,4,8,11-tetraazacyclotetradecane-5,12-dione, followed by LiAlH4 reduction results in the formation of FcCyclam. Metal complexes of FcCyclam with M2+ = Co2+, Ni2+, Cu2+, and Zn2+ were synthesized from FcCyclam and the respective metal triflates. The complexation of Cu2+ and FcCyclam in CH3CN is preceeded by a rapid electron transfer, followed by a slower complex formation reaction and a reverse electron transfer. The protonation constants of FcCyclam and the stability constants for the Cu2+ complex of FcCyclam (logK = 9.26(4) for the formation of the [Cu(FcCyclam)]2+ complex) were determined in 1,4-dioxane/water 70:30 v/v, 0.1 mol dm-3, KNO3, 25°C. By using FcCyclam one can selectively sense the presence of Cu2+ ions in the presence of Ni2+, Zn2+, Cd2+, Hg2+, and Pb2+ with a very large ΔE≈200 mV, depending on pH. The X-ray crystal structures of FcCyclam and of complexes with Co2+, Ni2+, Cu2+, and Zn2+ were determined and Fe-M2+ distances obtained: Fe-Co2+ 395.9, Fe-Ni2+ 385.4, Fe-Cu2+ 377.7, and Fe-Zn2+ 369.0 pm. The redox potential of FcCyclam is influenced in a characteristic manner by the complexation of M2+. A linear correlation of 1/r?ΔE [r = distance Fe-M2+ from crystal data, ΔE = E1/2([M(FcCyclam)]2+)-E1/2(FcCyclam)] was found; this is indicative of a mainly Coulomb type interaction between the two metal centers. The nature of the Fe...M2+ interaction was also investigated by determining ΔE in several solvents (mixtures) of different dielectric constants ε. The expected relation of ΔE?1/ε was only found at very high values of ε. At ε 2+ leading to progessively smaller values of ΔE with lowered ε. The dependence of ΔE and ε can be calculated semiquantitatively by combining the Fuoss ion-pairing theory with the Coulomb model. Wiley-VCH Verlag GmbH, 2001.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical ac-ceptable excipients and use of the compounds to modulate the PI3K/ mTOR pathway

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/ or the mTOR pathway.

Synthesis of N1 -alkyl-1,4-diazepin-5-ones via Schmidt ring expansion chemistry

Reaction of 4-piperidone with alkyl bromides gave the corresponding N-alkyl-4-piperidones, and treatment of these with hydrazoic acid resulted in the Schmidt reaction to give the corresponding N1-alkyl-1,4-diazepin- 5-ones in good overall yield

HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases

The preparation and SAR of a series of iNOS inhibitors leading to the most potent compound, incorporating a (1,4)-5-imino thiazepane (R = n-Pr) is disclosed. A series of 3- and 5-imino analogs from oxazepane, thiazepane, and diazepane was prepared and eva